SS Innovations Achieves Key Milestone with Successful Pediatric Surgery

Surgical robotic technology company, SS Innovations International (OTC: SSII), has achieved a key milestone in pediatric surgery as the company announced on Monday that its flagship SSi Mantra surgical robotic system has been utilized to perform the first pyeloplasty procedure on an infant. The SSi Mantra has now been used in more than 1000 procedures, including cardiothoracic, head and neck, gynecology, urology and general surgeries.

The successful surgery was performed on a 12 month old baby weighing 8.5 kilograms (~17.6 pounds). by Dr. Chandra Mohan Vaddi at the Preeti Urology & Kidney Hospital in Hyderabad, India.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations stated that the surgical milestone is a testament to the precision and adaptability of the SSi Mantra in meeting the nuanced requirements of pediatric care.

“It underscores our commitment to extending state-of-the-art surgical options to all patient demographics, including the most vulnerable. From the very beginning, our vision for our surgical robotic system was to revolutionize healthcare for everyone, including children, ensuring that even the most delicate surgeries are performed with unmatched precision and care,” said Dr. Srivastava. “Words can hardly express the overwhelming joy and pride we feel as we witness the SSi Mantra Surgical Robotic System changing the trajectory of children’s lives.”

The SSi Mantra Surgical Robotic System has been granted regulatory approval in India, Guatemala and Indonesia, and is clinically validated in more than 60 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and European Union, and anticipates receiving approvals in the latter half of 2024 or 2025.

About SS Innovations International, Inc.

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at or LinkedIn for updates.



This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

SS Innovations Achieves Key Milestone with Successful Pediatric Surgery

Catie Corcoran

Biotech Editor